Skip to main content

Table 1 Characteristics of patients in the per-protocol population

From: Nitrous oxide/oxygen plus acetaminophen versus morphine in ST elevation myocardial infarction: open-label, cluster-randomized, non-inferiority study

 Nitrous oxide/oxygen plus acetaminophen (n = 315)Morphine (n = 329)
Age, years, mean ± SD61.9 ± 13.762.1 ± 13.0
Male sex, n (%)255 (81.0)249 (75.7)
Body mass index,a kg/m2n = 296n = 307
 Median (Q1; Q3)25.8 (23.7; 28.1)26.0 (23.9; 29.0)
 ≥30 kg/m2, n (%)42 (14.2)58 (18.9)
Smokers, n/N (%)147/314 (46.8)150/321 (46.7)
Diabetes,bn/N (%)36/312 (11.5)38/323 (11.8)
Hypertension, bn/N (%)131/312 (42.0)119/318 (37.4)
Hypercholesterolaemia, bn/N (%)82/305 (26.9)95/315 (30.2)
Family history of cardiovascular disease, n/N (%)94/274 (34.3)87/278 (31.3)
Previous coronary artery disease, n/N (%)55/311 (17.7)56/324 (17.3)
Thrombolysis, n (%)30 (9.5)46 (14.0)
Decision of angioplasty, n (%)296 (94.0)308 (93.6)
Treatments at baseline, n (%)
 Aspirin313 (99.4)323 (98.2)
 Other antiplatelet (clopidogrel, ticagrelor or prasugrel)301 (95.6)314 (95.4)
  Clopidogrel54 (17.1)56 (17.0)
  Ticagrelor168 (53.3)145 (44.1)
  Prasugrel81 (25.7)116 (35.3)
 Heparin136 (43.2)163 (49.5)
 Low-molecular-weight heparin159 (50.5)124 (37.7)
 Bivalirudin21 (6.7)32 (9.7)
 Anticoagulant (heparin, low-molecular-weight heparin or bivalirudin)307 (97.5)318 (96.7)
 Beta-blocker4 (1.3)0
 Glycoprotein IIb/IIIa inhibitor6 (1.9)9 (2.7)
 Anxiolytic2 (0.6)10 (3.0)
 Other treatment (administered in mobile intensive care unit)47 (14.9)69 (21.0)
Delay between chest pain and study treatment start, minutesn = 314n = 329
 Median (Q1; Q3)91.0 (65.0; 161.0)100.0 (62.0; 167.0)
Pain score on numeric rating scale at study treatment startn = 314n = 328
 Median (Q1; Q3)7.0 (5.0; 8.0)7.0 (5.0; 8.0)
  1. Q quartile, SD Standard deviation
  2. aBody mass index is the weight in kilograms divided by the square of the height in meters
  3. bTreated